Actelion is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion was founded in 1997 and its shares have been listed on the SWX Swiss Exchange (ticker symbol ALTN) since 5 April 2000. On 22 September 2008, Actelion shares traded for the first time as part of the blue-chip SMI® (Swiss Market Index).
The company is focused on the discovery, development, and commercialization of synthetic, small-molecule drugs as innovative treatments to serve high unmet medical needs.
Actelion combines the innovation, entrepreneurial spirit, and flexibility of biotech with the financial, risk management, regulatory, and commercial discipline of a large pharmaceutical company. It has the proven ability to discover new compounds and to rapidly move compounds from research through development to commercialization.
In particular, Actelion scientists were among the first to work in the field of endothelin receptor antagonists, including its lead product, Tracleer®.
Actelion has subsidiaries in more than 25 countries, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU Member States. These subsidiaries provide distribution, sales, and marketing services.
